EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

Maarten Postma, David Fisman, Norberto Giglio iD, Sergio Márquez-Peláez iD, Van Hung Nguyen, Andrea Pugliese iD, Jesús Ruiz-Aragón iD, Analia Urueña iD, Joaquin Mould-Quevedo iD

Vaccines · 11.06.2023 · 11 (6) · 1089

DOI: 10.3390/vaccines11061089 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 11.06.2023. Verfasst von Maarten Postma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University Medical Center Groningen, University of Groningen, P.O. Box 72, 9700 AB Groningen, The Netherlands. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seqirus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV, and QIVr, respectively), are recommended in older populations to provide higher immunogenicity and increased relative vaccine efficacy/effectiveness (rVE) than standard-dose vaccines. This review explores how efficacy and effectiveness data from randomized controlled trials and real-world evidence (RWE) are used in economic evaluations. Findings from published cost-effectiveness analyses (CEA) on enhanced influenza vaccines for older adults are summarized, and the assumptions and approaches used in these CEA are assessed alongside discussion of the importance of RWE in CEA. Results from many CEA showed that adjuvanted and high-dose enhanced vaccines were cost-effective compared with standard vaccines, and that differences in rVE estimates and acquisition price may drive differences in cost-effectiveness estimates between enhanced vaccines. Overall, RWE and CEA provide clinical and economic rationale for enhanced vaccine use in people ≥ 65 years of age, an at-risk population with substantial burden of disease. Countries that consider RWE when making vaccine recommendations have preferentially recommended aTIV/aQIV, as well as HD-TIV/HD-QIV and QIVr, to protect older individuals.

Schlagwörter

Stichwörter der Autor:innen

adjuvantedcost-effectiveness analysisenhanced vaccineinfluenza

Autor:innen und Institutionen

  • Department of Health Sciences, University Medical Center Groningen, University of Groningen, P.O. Box 72, 9700 AB Groningen, The Netherlands.
  • Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, 9713 AB Groningen, The Netherlands.
  • Centre of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, 40132 Bandung, Indonesia.
  • Dalla Lana School of Public Health, Toronto, ON M5T 3M7, Canada.
  • Hospital de Niños Ricardo Gutièrrez, Buenos Aires 1425, Argentina.
  • Department of Economics, Economic Analysis, Faculty of Business Pablo de Olavide University, 41013 Seville, Spain.

ORCID-Profile: Norberto Giglio, Sergio Márquez-Peláez, Andrea Pugliese, Jesús Ruiz-Aragón, Analia Urueña, Joaquin Mould-Quevedo

Förderung

  • Seqirus

Zitieren

APA

Postma, M., Fisman, D., Giglio, N., Márquez-Peláez, S., Nguyen, V. H., Pugliese, A., Ruiz-Aragón, J., Urueña, A., & Mould-Quevedo, J. (2023). Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion. Vaccines, 11(6), 1089. https://doi.org/10.3390/vaccines11061089

Vancouver

Postma M, Fisman D, Giglio N, Márquez-Peláez S, Nguyen VH, Pugliese A, et al. Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion. Vaccines. 2023;11(6):1089. doi:10.3390/vaccines11061089

BibTeX
@article{Postma2023,
  author = {Postma, Maarten and Fisman, David and Giglio, Norberto and Márquez-Peláez, Sergio and Nguyen, Van Hung and Pugliese, Andrea and Ruiz-Aragón, Jesús and Urueña, Analia and Mould-Quevedo, Joaquin},
  title = {Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {6},
  pages = {1089},
  doi = {10.3390/vaccines11061089}
}
Kostenlos starten →